DRRX beat EPS expectations by 42.81%
Aug 16, 2025, 10:31 AM
-1.04%
What does DRRX do
DURECT, based in Cupertino, California, develops investigational therapies, including Larsucosterol for alcohol-associated hepatitis. Its FDA-approved products include POSIMIR and PERSERIS, while employing 48 staff since its 2000 IPO.
Durect (DRRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Durect's actual EPS was -$0.07, beating the estimate of -$0.12 per share, resulting in a 42.81% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.